HOME | COUNTRIES | CITIES | COMPANIES | SPORTS | CARS
news videos images websites wiki
 

Mylan NEWS

NFE/5.0en-USnews-webmaster@google.com2019 Google Inc.Tue, 22 Jan 2019 06:00:27 GMTGoogle News
Mylan/Apicore Challenged Over Imaging Agent Patents (1)  Bloomberg Law

Mylan NV and Apicore LLC are facing a challenge to their dominance in the market for isosulfan blue, a diagnostic imaging agent used to locate cancer, from ...

Bloomberg Law
Ironwood/Allergan Settle Linzess Patent Litigation With Mylan  Zacks.com

Ironwood (IRWD) and Allergan announce agreement with Mylan to resolve patent litigation, granting Mylan license to launch a generic version of Linzess in the ...

Zacks.com
AHIP takes aim at duplicative patents in Mylan case  FierceHealthcare

AHIP is requesting that the Supreme Court review a district court decision involving duplicative patents for the same drug. It argued that this tactic leads to higher ...

FierceHealthcare
Is Mylan (MYL) a Great Value Stock Right Now?  Zacks.com

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless ...

Zacks.com
These are the reimbursements of investing in these names: Mylan N.V. (MYL), Sealed Air Corporation (SEE)  FinBulletin

Throughout the past nine days on the trading calendar, Mylan N.V. (NASDAQ: MYL) shares demonstrated a Historic Volatility of 19.88%. That figure, when ...

FinBulletin
Allergan and Ironwood settle Linzess patent litigation with Mylan  Seeking Alpha

Ironwood Pharmaceuticals (IRWD) and development partner Allergan (AGN) have settled their patent infringement litigation against Mylan (MYL) related to the.

Seeking Alpha
Mylan NV (MYL) estimated to achieve 66.60% EPS growth for this year  Wallstreet Investorplace

Out of the important value indicator of stocks, EPS growth rate is most important. It will depend on the stock, the industry and the interest rates. Some stocks ...

Wallstreet Investorplace
Mylan N.V. (MYL) Moves Back And Forth on Volume Analysis  Investing News Update

Mylan N.V. (MYL) stock price 4.47% upward depiction highlighted by the trends created around 20 day SMA. The established trader's sentiment toward the stock ...

Investing News Update
Mylan Inc (MYL) CEO Heather Bresch Presents at 37th Annual J.P. Morgan Healthcare Conference (Transcript)  Seeking Alpha

Mylan Inc (NASDAQ:MYL) 37th Annual J.P. Morgan Healthcare Conference January 08, 2019, 02:00 PM ET Company Participants Heather Bresch - CEO Rajiv ...

Seeking Alpha
Sivik Global Healthcare Has Lowered Mylan Nv (MYL) Holding as Share Price Declined; Bridge Bancorp (BDGE) Holder Basswood Capital Management Lifted Holding by $5.77 Million  The Moveefy

Sivik Global Healthcare Llc decreased its stake in Mylan Nv (MYL) by 40.63% based on its latest 2018Q3 regulatory filing with the SEC. Sivik Global Healthcare ...

The Moveefy
Mylan NV (NasdaqGS:MYL)'s Volatility Moves the Target Weight to 0.02940  Felton News

A recent look at ownership and volatility brings us to a 0.02940 target portfolio weight (as a decimal) for Mylan N.V. (NasdaqGS:MYL) Target weight is the ...

Felton News
Mylan NV - Consenus Indicates Potential 44.3% Upside  DirectorsTalk Interviews

Mylan N.V. found using ticker (MYL) have now 16 analysts covering the stock. The analyst consensus points to a rating of 'Buy'. The range between the high.

DirectorsTalk Interviews
Top Analyst Pounds the Table on Mylan N.V. (MYL), Delphi Technologies PLC (DLPH)  The RNS Daily

A look at its monthly performance shows that Mylan N.V. (NASDAQ:MYL) has recorded a 2.46% gain over the past 30 days. Over the past 12 months the stock ...

The RNS Daily
Options Are Looking Quite Attractive: Mylan N.V. (MYL), CNO Financial Group, Inc. (CNO)  NMSU Nеws

Campbell Paul, See Remarks, sold 7,030 shares of the Mylan N.V. (NASDAQ:MYL) in an exchange that happened on March 6th. The stock was sold at an ...

NMSU Nеws
Trading Watch: Checking the Numbers on Shares of Mylan NV Ord Shs (MYL)  Olla Journal

Let's check in on some recent stock price information on shares of Mylan NV Ord Shs (MYL). At the time of writing, shares had most recently hit 29.59. The stock.

Olla Journal
Mylan Nv (MYL) Shareholder Kirr Marbach & Company Raised Position by $712,980 as Shares Declined; Strategy Asset Managers Cut Its Accenture Plc Ireland (ACN) Position by $93.78 Million as Share Value Declined  The Moveefy

Kirr Marbach & Company Llc increased its stake in Mylan Nv (MYL) by 10.12% based on its latest 2018Q3 regulatory filing with the SEC. Kirr Marbach ...

The Moveefy
Mylan snaps up HIV-focused South African facility from Ascendis for $9.4M  FiercePharma

Mylan shelled out $9.4 million for Ascendis Health's South African manufacturing plant that is focused on producing antiretrovirals to combat HIV.

FiercePharma
Regent Investment Management Has Raised Position in Mylan Nv F (MYL) by $389,700 as Shares Declined; Lauder Estee Cos (EL) Holding Raised by Ycg Llc  The Yomi Blog

Regent Investment Management Llc increased its stake in Mylan Nv F (MYL) by 14.08% based on its latest 2018Q3 regulatory filing with the SEC. Regent ...

The Yomi Blog
Mylan N.V. (MYL) Appears To Be In Wait-and-See Mode  KYMA News

If you can handle volatility, Mylan N.V. (NASDAQ:MYL) is the stock to watch now. The stock closed lower on 16 January. The shares dropped -0.09 points or ...

KYMA News
Hormone Replacement Therapy (HRT) Market 2019 – Survey, Development Analysis and Precise Growth Outlook: Mylan Laboratories, Amgen, Novo Nordisk, Wyeth, Genentech  Bitcoin Journal

Recently Published market study “Global Hormone Replacement Therapy (HRT) Market Size, Status And Forecast 2019-2025” in-depth analysis of the market ...

Bitcoin Journal
Evanston Investments Dba Evanston Advisors Has Boosted Position in Mylan NV (MYL); International Business Machs (IBM) Holder Taylor Asset Management Lowered Its Stake as Shares Declined  The Yomi Blog

Evanston Investments Inc Dba Evanston Advisors increased its stake in Mylan N.V. (MYL) by 4.17% based on its latest 2018Q3 regulatory filing with the SEC.

The Yomi Blog
Sandoz launches cheaper EpiPen rival  In-PharmaTechnologist.com

Sandoz becomes the latest company to launch a generic version of Mylan's EpiPen in the US and has undercut its rivals on pricing. As had been expected​, ...

In-PharmaTechnologist.com
Insiders Are Selling Big on Mylan N.V. (MYL)  KYMA News

With 30 sell/buy ratio, Mylan N.V. (NASDAQ:MYL) experienced more insider selling than buying over the last twelve months. Could this be a sign for outside ...

KYMA News
Global Valsartan Drug Market Value 2019-2026 Sun Pharmaceutical, Mylan, Aurobindo Pharma.  reportsherald.com

QY Market Study recently introduced “Valsartan Drug market research study 2019-2026” with in-depth targeted approach on qualitative analysis, describing ...

reportsherald.com
As Mylan NV (MYL) Share Price Declined, Shareholder Victory Capital Management Has Lifted Its Holding; Us Bancorp De Has Cut Wabco Hldgs (WBC) Stake by $665,145 as Stock Price Declined  The FinHeadLines

Victory Capital Management Inc increased its stake in Mylan N V (MYL) by 50.82% based on its latest 2018Q3 regulatory filing with the SEC. Victory Capital ...

The FinHeadLines
Stoneridge Investment Partners Increased Its Mylan (MYL) Stake; 7 Analysts Are Bullish AstraZeneca PLC (LON:AZN) Last Week  The FinHeadLines

Among 14 analysts covering AstraZeneca PLC (LON:AZN), 7 have Buy rating, 0 Sell and 7 Hold. Therefore 50% are positive. AstraZeneca PLC had 67 analyst ...

The FinHeadLines
Menora Mivtachim Holdings LTD Upped Holding in Mylan NV (MYL) as Share Price Declined; As Compass Minerals Intl (CMP) Market Valuation Declined, Lapides Asset Management Has Increased Its Holding  The FinHeadLines

Menora Mivtachim Holdings Ltd increased its stake in Mylan N V (MYL) by 2.72% based on its latest 2018Q3 regulatory filing with the SEC. Menora Mivtachim ...

The FinHeadLines
Further Upside Possible :: Mylan NV, (NASDAQ: MYL)  Top Stocks News

EPS growth is an important number as it gives a suggestion of the future prospects of a company. It is usually expressed as a percentage and is then referred to ...

Top Stocks News
As Mylan Nv (MYL) Market Valuation Declined, Kirr Marbach & Company Has Raised Holding; Mcdonalds (MCD) Shareholder Chatham Capital Group Has Increased Its Holding  The Yomi Blog

Chatham Capital Group Inc increased its stake in Mcdonalds Corp (MCD) by 12.52% based on its latest 2018Q3 regulatory filing with the SEC. Chatham Capital ...

The Yomi Blog
Ignore The Doomsayers: Reasons To Watch Kimco Realty Corporation (KIM), Mylan N.V. (MYL)  GV Times

The shares of Kimco Realty Corporation (NYSE:KIM) has performed better over the past three months, as it added around 5.87% while it has so far retreated ...

GV Times
Mylan Nv Ord Shs (MYL) Ichimoku Levels Indicate Negative Trend  MTL News

Mylan Nv Ord Shs (MYL) shares opened the last session at 29.76, touching a high of 29.94 and a low of 29.29 , yielding a change of 0.04. The latest reading ...

MTL News
Placing Newell Brands Inc. (NasdaqGS:NWL), Mylan NV (NasdaqGS:MYL) Quant Signals Under the Microscope  Hawthorn Caller

Newell Brands Inc. (NasdaqGS:NWL) has a Q.i. Value of 27.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF.

Hawthorn Caller
US Xpress Enterprises, Inc. (USX) Analysts See $0.40 EPS; Partner Investment Management LP Increased Mylan NV (MYL) Position  The FinHeadLines

Analysts expect U.S. Xpress Enterprises, Inc. (NYSE:USX) to report $0.40 EPS on February, 7.USX's profit would be $19.32M giving it 4.63 P/E if the $0.40 EPS ...

The FinHeadLines
Triumph Group (TGI) Market Valuation Declined While Mcclain Value Management Has Upped by $1.27 Million Its Position; Mylan Nv (MYL) Holder Sivik Global Healthcare Has Decreased Its Holding  The Moveefy

Sivik Global Healthcare Llc decreased its stake in Mylan Nv (MYL) by 40.63% based on its latest 2018Q3 regulatory filing with the SEC. Sivik Global Healthcare ...

The Moveefy
As Mylan Nv Shs Euro (MYL) Stock Price Declined, New York State Teachers Retirement System Has Lifted Position; Theleme Partners Llp Trimmed Stake in Schwab Charles New (SCHW) as Market Valuation Declined  The Hi New Ulm

Theleme Partners Llp decreased its stake in Schwab Charles Corp New (SCHW) by 3.15% based on its latest 2018Q3 regulatory filing with the SEC. Theleme ...

The Hi New Ulm
Mylan Park hosts fourth annual Small Town Bridal Show and Wedding Market  WBOY.com

There's no better time to start planning a wedding than at the beginning of a new year, and on Sunday hundreds of brides made their way to Morgantown for the ...

WBOY.com
Global Acamprosate Calcium Market Major Players Analysis 2019 : Mylan, Merck, Teva, Zydus Pharmaceuticals  World News Today

A market study on the ” Global Acamprosate Calcium Market ” Research Report 2019-2026 By QY Market Study. It analyses the important factors of the ...

World News Today
Evanston Investments Dba Evanston Advisors Increased Mylan NV (MYL) Position by $311,040; Kraton (KRA) Share Value Declined While Prudential Financial Has Increased Position by $321,950  The FinExaminer

Evanston Investments Inc Dba Evanston Advisors increased its stake in Mylan N.V. (MYL) by 4.17% based on its latest 2018Q3 regulatory filing with the SEC.

The FinExaminer
Updated Analysts Rating Report: Mylan NV (MYL)  Nasdaq Click

Mylan N.V. (MYL) stock price ended its day with gain 0.14% and finalized at the price of $29.59, its 52 week- peak value and changed 13.66% from its 52 ...

Nasdaq Click
Trading Update for Mylan NV Ord Shs (MYL)  Northfield Review

Share Performance ReviewTaking a quick look at recent session activity on shares of Mylan NV Ord Shs (MYL), we can see that the stock price.

Northfield Review
Global Doxycycline Injection Market Analysis 2019: Mylan, Zydus Pharmaceuticals, Fresenius Kabi  reportsherald.com

QY Market Study recently introduced “Doxycycline Injection market research study 2019-2026” with in-depth targeted approach on qualitative analysis, ...

reportsherald.com
Confluence Investment Management Cut Fidelity National Financial In (FNF) Position by $1.87 Million as Market Valuation Declined; Texas Permanent School Fund Cut Its Stake in Mylan NV (MYL) as Stock Price Declined  The Hi New Ulm

Confluence Investment Management Llc decreased its stake in Fidelity National Financial In (FNF) by 1.97% based on its latest 2018Q3 regulatory filing with the ...

The Hi New Ulm
Showmasters Gun Show brings several vendors to Mylan Park  WBOY.com

The Showmasters Gun Show was held this weekend in Morgantown.

WBOY.com
As Mylan NV (MYL) Share Value Declined, Chevy Chase Trust Holdings Lowered Its Stake by $373,896; First Horizon Natl (FHN) Stock Declined While Pennsylvania Trust Co Has Upped Its Stake  EN Digest

Chevy Chase Trust Holdings Inc decreased its stake in Mylan N V (MYL) by 2.39% based on its latest 2018Q3 regulatory filing with the SEC. Chevy Chase Trust ...

EN Digest
Mylan NV (MYL) Shareholder Partner Fund Management LP Raised Position; Chase Investment Counsel Has Decreased Its E Trade Financial (ETFC) Holding by $550,628; Stock Value Declined  The FinReviewer

Partner Fund Management Lp increased its stake in Mylan N V (MYL) by 269.03% based on its latest 2018Q3 regulatory filing with the SEC. Partner Fund ...

The FinReviewer
Barometer Capital Management Trimmed Holding in Svb Financial Group (SIVB) as Valuation Declined; Gideon Capital Advisors Increases Position in Mylan NV (MYL)  The FinExaminer

Barometer Capital Management Inc decreased its stake in Svb Financial Group (SIVB) by 7.12% based on its latest 2018Q3 regulatory filing with the SEC.

The FinExaminer
FDA Approves Third Trastuzumab Biosimilar, Ontruzant  The Center for Biosimilars

The FDA has approved Samsung Bioepis' Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive ...

The Center for Biosimilars
Blair William & Company Has Trimmed Holding in Fedex (FDX) as Stock Declined; As Mylan NV (MYL) Valuation Declined, Ascend Capital Lifted Stake by $40.09 Million  The FinReviewer

Blair William & Company decreased its stake in Fedex Corp (FDX) by 33.83% based on its latest 2018Q3 regulatory filing with the SEC. Blair William & Company ...

The FinReviewer
Philip Morris Intl (PM) Holder Park Circle Co Boosted Position by $1.11 Million; As Mylan NV (MYL) Share Value Declined, Partner Investment Management LP Boosted by $1.79 Million Its Stake  The FinHeadLines

Park Circle Co increased its stake in Philip Morris Intl Inc (PM) by 33.97% based on its latest 2018Q3 regulatory filing with the SEC. Park Circle Co bought ...

The FinHeadLines
Current Fundamentals:: Mylan N.V., (NASDAQ: MYL)  Nyse News Updates

Market capitalization (market cap) is the market value of a publicly traded company's outstanding shares. Market capitalization is equal to the share price ...

Nyse News Updates
Mylan: On The Road To Recovery  Seeking Alpha

5% EPS beat and reiterated guidance signals Mylan is getting back on track. Approval for Mylan's generic asthma treatment looks imminent. Plant restructuring ...

Seeking Alpha
Global Opioids Drug Market 2019- Purdue Pharma, J&J, Teva, Mylan  reportsherald.com

The Global Opioids Drug Market report enfolds crucial statistical data of sales and revenue based on leading segment such as type, applications, regions, ...

reportsherald.com
As Core Laboratories NV (CLB) Share Value Declined, Corecommodity Management Raised Holding; Kirr Marbach & Company Holding In Mylan Nv (MYL) Was Boosted  The FinHeadLines

Corecommodity Management Llc increased its stake in Core Laboratories N V (CLB) by 288.28% based on its latest 2018Q3 regulatory filing with the SEC.

The FinHeadLines
Mylan stock drops 3% after wipeout of a second quarter  MarketWatch

Chief Executive Heather Bresch, who became the poster child for pharmaceutical villainy over EpiPen price hikes in 2016, also critiqued the U.S. drug pricing ...

MarketWatch
Mylan: Blank Check On Growth?  Seeking Alpha

Mylan, one of the leading generic companies, is traded at multi-year lows with a striking 2018 P/E multiple of 6x. There are many reasons for concern, including.

Seeking Alpha
Global Self Injection Device Market 2019: Pfizer, Sanofi, BD, Eli Lilly, Novo Nordisk, Mylan  Bitcoin Journal

Global Self Injection Device Market is rapidly exhibiting escalating growth rate since last decade. Improved technologies, sufficient workforce, advanced support ...

Bitcoin Journal
Wall Street thought Mylan was headed for disaster—now, analysts are raving  MarketWatch

The stock slid nearly 20% since August, but jumped more than 13% after new financial results.

MarketWatch
FDA warns Mylan over Morgantown plant  Pittsburgh Business Times

Mylan NV said late Tuesday it was working to satisfy the U.S. Food and Drug Administration after the FDA sent a warning letter to the generic pharmaceutical ...

Pittsburgh Business Times
Why Mylan N.V. Stock Is Soaring Today  Motley Fool

Shares of Mylan N.V. (NASDAQ:MYL) are soaring today, up 16.4% as of 11:40 a.m. EST, after the drugmaker reported better-than-expected Q3 earnings ...

Motley Fool
Mylan Expands Voluntary Nationwide Recall of Valsartan Tablets  Pharmacy Times

Officials with Mylan Pharmaceuticals today announced that they are expanding a consumer-level voluntary nationwide recall to include all lots of ...

Pharmacy Times
Global Raynaud's Phenomenon Management Market 2019 – Sanofi-Aventis, GlaxoSmithKline, TEVA Pharmaceuticals Industries, Mylan  Global Info Research

The *fresh* report released by Fior Markets namely, Global Raynaud's Phenomenon Management Market 2018 by Manufacturers, Countries, Type and ...

Global Info Research
Global Estradiol/Norethindrone Acetate drug Market Players Analysis 2019: Amneal, Mylan, Teva, Novo Nordisk  reportsherald.com

QY Market Study recently introduced “Estradiol/Norethindrone Acetate drug market research study 2019-2026” with in-depth targeted approach on qualitative ...

reportsherald.com
Mylan upgraded to buy at CFRA on expectations its worst days are over  MarketWatch

CFRA upgraded Mylan NV stock MYL, +0.14% on Thursday to buy from hold, and said the company's worst days are over. Mylan stock is trading at a five-year ...

MarketWatch
Patience Will Be Required For Sandoz And Adamis' 'Phased' Launch Of Symjepi  Seeking Alpha

Sandoz and Adamis announce commercial launch for SYMJEPI in the U.S. Investors still waiting for SYMJEPI Jr. and potential ex-U.S. strategy. Sandoz intends ...

Seeking Alpha
Mylan's Morgantown plant draws warning letter from FDA  Pittsburgh Post-Gazette

The U.S. Food and Drug Administration has issued a warning letter to local drugmaker Mylan for “significant violations” of manufacturing regulations at its ...

Pittsburgh Post-Gazette
3 Headwinds Hindering Mylan (NASDAQ:MYL)  Benzinga

Even with positive near-term catalysts, Mylan NV (NASDAQ: MYL) suffers from “uncertain prospects” that warrant a neutral stance, according to ...

Benzinga
Taking aim at Medicaid misclassifications like Mylan's EpiPen, senators look to end a 'pharma ripoff'  FiercePharma

Two senators introduced a bill cracking down on drug misclassifications that cost Medicaid—and taxpayers—millions in underpaid rebates. In some cases, the ...

FiercePharma
Mylan recalls batches of blood pressure medicine in U.S.  Reuters

(Reuters) - Mylan NV said on Tuesday it would recall certain batches of blood pressure medicine valsartan in the United States after they were found to contain a ...

Reuters
Should You Bet On Transdermal Drug Delivery?  Forbes

Delivering drugs through a patch sounds good. But can you make money investing in it? Not likely. But a Quebec company is working with Tilray to get you a ...

Forbes
Three more blood pressure drugs recalled over cancer concern: Here's what you need to know  USA TODAY

Mylan Pharmaceuticals has recalled three common blood pressure medications over concerns they could include small amounts of a cancer-causing impurity.

USA TODAY
Advair copy approval 'imminent,' Mylan says, but investors jittery  BioPharma Dive

An approval of Mylan's generic Advair copy by the Food and Drug Administration should be coming any day now, the drugmaker said Monday, seeking to head ...

BioPharma Dive
Roche dominates 2019’s big patent expirations  Vantage

Of the five biggest products set to lose exclusivity in the US this year, the Swiss pharma giant owns three of them: Avastin, Herceptin and Tarceva. Hourglass.

Vantage
Mylan stock drops 5% after Q2 misses, slashed 2018 guidance and board plans to evaluate 'alternatives'  MarketWatch

Mylan NV MYL, -0.62% shares dropped 5% in Wednesday premarket trade after the company's board of directors said it is evaluating "a wide range of ...

MarketWatch
Mylan to recall all batches of blood pressure medicine valsartan in US  CNBC

Mylan NV said on Tuesday it is issuing a nationwide voluntary recall of all lots of its blood pressure medicine valsartan, expanding a recall of select batches ...

CNBC
Global Thyroid Cancer Treatment Market 2019 – Baxter, Mylan, Alara, Bristol Myers, Abbott, Teva, Teva, Jerome Stevens  Bitcoin Journal

The comprehensive study on Global Thyroid Cancer Treatment Market report includes historic data, present market trends, environment, technological ...

Bitcoin Journal
Mylan overhaul of West Virginia plant has a ways to go  FiercePharma

While Mylan's third-quarter results impressed analysts, the generics drugmaker is still dealing with some significant manufacturing issues, some of them not of its ...

FiercePharma
Teva prices EpiPen generic at $300, same price as Mylan generic  CNBC

Teva Pharmaceutical Industries said on Tuesday it launched its generic version of Mylan's EpiPen at the wholesale price of $300 - the same price as Mylan's ...

CNBC
Mylan's Issues Persist But Expectations Are Low And Several Catalysts Are Coming  Seeking Alpha

While investors have long criticized Mylan's new product yield, a generic Advair and Restasis could finally be coming to market before the end of the year. In t.

Seeking Alpha
EpiPen class action lawsuit against Mylan, Pfizer to continue, judge rules  BioPharma Dive

A class action lawsuit claiming Pfizer and Mylan violated antitrust and racketeering laws while managing the epinephrine auto-injector franchise EpiPen will ...

BioPharma Dive
Probe of generic 'cartel' suspects — including Mylan and Teva — grows to 300 drugs  Pittsburgh Post-Gazette

Executives at more than a dozen generic-drug companies had a form of shorthand to describe how they conducted business, insider lingo worked out over steak ...

Pittsburgh Post-Gazette
Mylan Suffers Several Setbacks: What's in Store in 2H18?  Zacks.com

Mounting competition and recent setbacks cast a pall over Mylan's (MYL) near-term performance.

Zacks.com
What Mylan Could Learn About Accountability  Life Science Leader Magazine

Mylan's inability to adequately supply its EpiPen during the 2018 back-to-school time is the latest example of corporate leadership lacking...

Life Science Leader Magazine
Q&A: Rajiv Malik, Mylan  Pharmaceutical Executive

A Q&A with Mylan's President, Rajiv Malik about what progresses our society has made to fight HIV, what challenges companies face in tackling medicine ...

Pharmaceutical Executive
Mylan Stock Dips Though Analyst Bullish On Biosimilars  Investor's Business Daily

Mylan stock slid Tuesday as investors digested the generic pharmaceutical company's biosimilar strategy, EpiPen sales and upcoming third-quarter report.

Investor's Business Daily
Mylan Reports Third Quarter 2018 Results and Reaffirms 2018 Guidance  PR Newswire

HERTFORDSHIRE, England and PITTSBURGH, Nov. 5, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its financial results for the quarter ...

PR Newswire
Mylan Stock Rises As Generic Pharma Keeps 2018 Guide Despite Sales Dip  Investor's Business Daily

Mylan stock jumped late on Monday after the generic pharma reported adjusted income of $1.25 per share on $2.86 billion in sales for its third quarter.

Investor's Business Daily
Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards?  Zacks.com

Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when it reports Q3 results.

Zacks.com
FDA approves first generic EpiPen in blow to Mylan  USA TODAY

The EpiPen is getting a *fresh* dose of competition. The Food and Drug Administration on Thursday approved what it described as the first official generic version ...

USA TODAY
Global Treatment and Prevention of Herpes Labialis Market 2019 – GSK, Novartis, Teva, Mylan, Cadila, Apotex, Apotex  Bitcoin Journal

The comprehensive study on Global Treatment and Prevention of Herpes Labialis Market report includes historic data, present market trends, environment, ...

Bitcoin Journal
European authorities suspend Mylan's manufacturing license for hypertension drug  Pittsburgh Business Times

Mylan NV's manufacturing license for valsartan was suspended by European authorities after NDEA was found in some batches of the hypertension drug made ...

Pittsburgh Business Times
FDA Approves Samsung Bioepis's Trastuzamab Biosimilar | Goodwin  JD Supra

Today, the FDA approved Samsung Bioepis's Ontruzant (trastuzumab-dttb), a biosimilar to Genentech's Herceptin (trastuzumab), for the treatment of patients ...

JD Supra
Many US Pharmacies Out of Mylan Auto-Injectors, as Shortage Drags On  Allergic Living

The last time that Clarence Sullivan, owner of The Pharmacy Shop in Lexington, Kentucky, received a shipment of Mylan NV's EpiPen, EpiPen Jr or equivalent ...

Allergic Living
Mylan recalls blood pressure drugs that contain Valsartan over cancer concern  CBS News

Prescription drugs sold nationwide may contain trace amounts of probable carcinogen also found in tobacco smoke.

CBS News
Mylan Strikes $463 Million Deal With Novartis for CF Product Line  BioSpace

Mylan plunked down $463 million for Novartis' cystic fibrosis products, which includes the TOBI Podhaler and TOBI solution.

BioSpace
Ligand Pharmaceuticals (LGND) Shareholder Woodstock Trimmed Position as Share Price Declined; As Mylan NV (MYL) Valuation Declined, Evanston Investments Dba Evanston Advisors Has Upped Stake  D Minute

Woodstock Corp decreased its stake in Ligand Pharmaceuticals Inc (LGND) by 1.75% based on its latest 2018Q3 regulatory filing with the SEC. Woodstock Corp ...

D Minute
FDA Issues Warning Letter to Mylan for Pharma Manufacturing Facility  Pharmaceutical Technology Magazine

FDA has issued a warning letter to Mylan citing GMP violations of finished pharmaceutical products manufactured at the company's Morgantown, WV, facility.

Pharmaceutical Technology Magazine
Mylan stock rises 3% after upgraded to outperform by EvercoreISI  MarketWatch

Mylan NV MYL, -0.31% shares rose 2.9% in Friday premarket trade after the company was upgraded to outperform by EvercoreISI analyst Umer Raffat on the ...

MarketWatch
Morgantown restructuring costs weigh on Mylan  BioPharma Dive

Following a Food and Drug Administration inspection of its Morgantown, West Virginia, facility in March and April, Mylan began a restructuring program aimed at ...

BioPharma Dive
Why Mylan, Mosaic, and Martin Marietta Materials Jumped Today  Motley Fool

Tuesday was a good day for the stock market, with major benchmarks all moving higher. Nearly all of the attention among investors remained squarely on ...

Motley Fool
Mylan wins patent dispute with Sanofi over insulin product  MarketWatch

Mylan NV shares MYL, +0.14% were slightly higher Thursday, afger the company said the U.S. Patent and Trademark Appeal board had ruled in its favor in a ...

MarketWatch
 

Mylan Videos

Mylan
21:44:38
Mylan
MYLAN IS PURSUING SOLO CAREER
21:00:00
MYLAN IS PURSUING SOLO CAREER
Mylan France
12:39:54
Mylan France
How Mylan Tablets and Capsules are Made
18:49:27
How Mylan Tablets and Capsules are Made
Mylan - Websérie VIH/SIDA - L'histoire d'Eva
13:43:36
Mylan - Websérie VIH/SIDA - L'histoire d'Eva
\
03:35:11
\"That's Why We Don't Trust You\" Jason Chaffetz Shocks Mylan CEO
MYLAN CUT HIS HAIR!!
00:12:24
MYLAN CUT HIS HAIR!!
About Mylan Group
08:17:41
About Mylan Group
We Are Mylan
15:06:13
We Are Mylan
Teva Pharmaceuticals makes $40 billion bid for Mylan
16:03:10
Teva Pharmaceuticals makes $40 billion bid for Mylan
 

Mylan Images

Extracts from Interview with Heather Bresch, CEO of Mylan ...
Extracts from Interview with Heather Bresch, CEO of Mylan ...
Mylan's Upgraded EpiPen Torn Apart By Experts - NBC News
Mylan's Upgraded EpiPen Torn Apart By Experts - NBC News
Olmesartan Medoxomil 20mg 30 Tab Gen Benicar by Mylan
Olmesartan Medoxomil 20mg 30 Tab Gen Benicar by Mylan
Anti-allergy medicine EpiPen recall expands to US
Anti-allergy medicine EpiPen recall expands to US
Alprazolam - wikidoc
Alprazolam - wikidoc
How to give Epipen - Australasian Society of Clinical ...
How to give Epipen - Australasian Society of Clinical ...
Econazole Mylan 1 % Emulsion - Médicament Mycoses ...
Econazole Mylan 1 % Emulsion - Médicament Mycoses ...
Ibuprofene Mylan 400 mg cpr. - Pharmily
Ibuprofene Mylan 400 mg cpr. - Pharmily
Macrogol 4000 10G MYLAN 20 BORSE
Macrogol 4000 10G MYLAN 20 BORSE
Katee Sackhoff | NewDVDReleaseDates.com
Katee Sackhoff | NewDVDReleaseDates.com
 

Mylan WebSites

 

Mylan Wiki

Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan grew from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world.Mylan went public on the OTC market in February 1973. It is listed on the NASDAQ, and its shares are a component of NASDAQ Biotechnology,NASDAQ-100, and the S&P 500 indices.The company develops and produces medicines for a wide range of medical disciplines, including oncology, anaphylaxis, antiretrovirals, cardiovascular, respiratory, dermatology, immunology, anesthesia and pain management, infectious disease, gastroenterology, diabetology/endocrinology, and women's healthcare.In 2016, Mylan's pricing of the EpiPen, an epinephrine autoinjector, became controversial and was widely referred to as "price gouging". As a result, investigations were opened into whether Mylan had misclassified the EpiPen under the Medicaid Drug Rebate Program, a common form of pharmaceutical fraud. In October 2016, Mylan settled these investigations with the U.S. Department of Justice, agreeing to pay $465 million and enter into a corporate integrity agreement concerning the rebate program. In a report published on June 12, 2017 Institutional Shareholder Services criticized Mylan for the "outsized compensation" of Mylan's directors. Former CEO Robert Coury received a $98 million 2016 pay package in spite of shareholder losses and the perceived harm to the company inflicted by the EpiPen controversies. The report urged Mylan's shareholders to oust all of Mylan's existing directors.